

# **2019 Future of Progressive Supranuclear Palsy (PSP) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments**

<https://marketpublishers.com/r/2F07FC30DDDEN.html>

Date: February 2019

Pages: 65

Price: US\$ 2,199.00 (Single User License)

ID: 2F07FC30DDDEN

## **Abstracts**

The global demand for Progressive Supranuclear Palsy (PSP) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Progressive Supranuclear Palsy (PSP) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Progressive Supranuclear Palsy (PSP) pipeline companies from advancing their products into Phase 3 or Phase 4.

### **Progressive Supranuclear Palsy (PSP) Report Description-**

The 2019 pipeline study on Progressive Supranuclear Palsy (PSP) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Progressive Supranuclear Palsy (PSP) pipeline compounds.

The Progressive Supranuclear Palsy (PSP) pipeline guide presents information on all active drugs currently being developed for Progressive Supranuclear Palsy (PSP). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Progressive Supranuclear Palsy (PSP) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Progressive Supranuclear Palsy (PSP) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Progressive Supranuclear Palsy (PSP) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Progressive Supranuclear Palsy (PSP) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Progressive Supranuclear Palsy (PSP) pipeline report includes-

An overview of Progressive Supranuclear Palsy (PSP) disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Progressive Supranuclear Palsy (PSP) pipeline

Company wise list of Progressive Supranuclear Palsy (PSP) pipeline

Mechanism of Action wise Progressive Supranuclear Palsy (PSP) pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

## **REASONS TO BUY**

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Progressive Supranuclear Palsy (PSP) pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Progressive Supranuclear Palsy (PSP) pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Progressive Supranuclear Palsy (PSP) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

## Contents

### 1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

### 2. GLOBAL PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

### 3. EXECUTIVE SUMMARY

- 3.1 Progressive Supranuclear Palsy (PSP) Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
  - 3.2.1 Pre-clinical
  - 3.2.2 Discovery
  - 3.2.3 Phase
  - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
  - 3.3.1 Phase
  - 3.3.2 Pre-registration
- 3.4 Companies involved in Progressive Supranuclear Palsy (PSP) pipeline, H1- 2019
- 3.5 Mechanism of Action wise Progressive Supranuclear Palsy (PSP) Pipeline Candidates

### 4 ABBVIE INC PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS

- 4.1 AbbVie Inc Business Profile
- 4.2 AbbVie Inc Progressive Supranuclear Palsy (PSP) Drug Details
- 4.3 Drug Snapshot
  - 4.3.1 Originator
  - 4.3.2 Collaborator/Co-Developer
  - 4.3.3 Route of Administration
  - 4.3.4 Orphan Drug/Fast Track/Special Designation
  - 4.3.5 Geography
  - 4.3.6 Type of Molecular Entity

- 4.3.7 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

## **5 AC IMMUNE PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 5.1 AC Immune Business Profile
- 5.2 AC Immune Progressive Supranuclear Palsy (PSP) Drug Details
- 5.3 Drug Snapshot
  - 5.3.1 Originator
  - 5.3.2 Collaborator/Co-Developer
  - 5.3.3 Route of Administration
  - 5.3.4 Orphan Drug/Fast Track/Special Designation
  - 5.3.5 Geography
  - 5.3.6 Type of Molecular Entity
  - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

## **6 ALZPROTECT SAS PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 6.1 AlzProtect SAS Business Profile
- 6.2 AlzProtect SAS Progressive Supranuclear Palsy (PSP) Drug Details
- 6.3 Drug Snapshot
  - 6.3.1 Originator
  - 6.3.2 Collaborator/Co-Developer
  - 6.3.3 Route of Administration
  - 6.3.4 Orphan Drug/Fast Track/Special Designation
  - 6.3.5 Geography
  - 6.3.6 Type of Molecular Entity
  - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details

## 6.7 Latest Drug Developments

### **7 AQUINNAH PHARMACEUTICALS PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

#### 7.1 Aquinnah Pharmaceuticals Business Profile

#### 7.2 Aquinnah Pharmaceuticals Progressive Supranuclear Palsy (PSP) Drug Details

#### 7.3 Drug Snapshot

##### 7.3.1 Originator

##### 7.3.2 Collaborator/Co-Developer

##### 7.3.3 Route of Administration

##### 7.3.4 Orphan Drug/Fast Track/Special Designation

##### 7.3.5 Geography

##### 7.3.6 Type of Molecular Entity

##### 7.3.7 Current Status

#### 7.4 Drug Overview

#### 7.5 Drug Mechanism of Action

#### 7.6 Clinical/Pre-clinical Trial Details

#### 7.7 Latest Drug Developments

### **8 ASCENEURON SA PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

#### 8.1 Asceneuron SA Business Profile

#### 8.2 Asceneuron SA Progressive Supranuclear Palsy (PSP) Drug Details

#### 8.3 Drug Snapshot

##### 8.3.1 Originator

##### 8.3.2 Collaborator/Co-Developer

##### 8.3.3 Route of Administration

##### 8.3.4 Orphan Drug/Fast Track/Special Designation

##### 8.3.5 Geography

##### 8.3.6 Type of Molecular Entity

##### 8.3.7 Current Status

#### 8.4 Drug Overview

#### 8.5 Drug Mechanism of Action

#### 8.6 Clinical/Pre-clinical Trial Details

#### 8.7 Latest Drug Developments

### **9 BIOGEN INC PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 9.1 Biogen Inc Business Profile
- 9.2 Biogen Inc Progressive Supranuclear Palsy (PSP) Drug Details
- 9.3 Drug Snapshot
  - 9.3.1 Originator
  - 9.3.2 Collaborator/Co-Developer
  - 9.3.3 Route of Administration
  - 9.3.4 Orphan Drug/Fast Track/Special Designation
  - 9.3.5 Geography
  - 9.3.6 Type of Molecular Entity
  - 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

## **10 CORTICE BIOSCIENCES INC PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 10.1 Cortice Biosciences Inc Business Profile
- 10.2 Cortice Biosciences Inc Progressive Supranuclear Palsy (PSP) Drug Details
- 10.3 Drug Snapshot
  - 10.3.1 Originator
  - 10.3.2 Collaborator/Co-Developer
  - 10.3.3 Route of Administration
  - 10.3.4 Orphan Drug/Fast Track/Special Designation
  - 10.3.5 Geography
  - 10.3.6 Type of Molecular Entity
  - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

## **11 DECLION PHARMACEUTICALS INC PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 11.1 Declion Pharmaceuticals Inc Business Profile
- 11.2 Declion Pharmaceuticals Inc Progressive Supranuclear Palsy (PSP) Drug Details



- 11.3 Drug Snapshot
  - 11.3.1 Originator
  - 11.3.2 Collaborator/Co-Developer
  - 11.3.3 Route of Administration
  - 11.3.4 Orphan Drug/Fast Track/Special Designation
  - 11.3.5 Geography
  - 11.3.6 Type of Molecular Entity
  - 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

## **12 DELTA CRYSTALLON BV PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 12.1 Delta Crystallon BV Business Profile
- 12.2 Delta Crystallon BV Progressive Supranuclear Palsy (PSP) Drug Details
- 12.3 Drug Snapshot
  - 12.3.1 Originator
  - 12.3.2 Collaborator/Co-Developer
  - 12.3.3 Route of Administration
  - 12.3.4 Orphan Drug/Fast Track/Special Designation
  - 12.3.5 Geography
  - 12.3.6 Type of Molecular Entity
  - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

## **13 INTELLECT NEUROSCIENCES INC PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 13.1 Intellect Neurosciences Inc Business Profile
- 13.2 Intellect Neurosciences Inc Progressive Supranuclear Palsy (PSP) Drug Details
- 13.3 Drug Snapshot
  - 13.3.1 Originator
  - 13.3.2 Collaborator/Co-Developer

- 13.3.3 Route of Administration
- 13.3.4 Orphan Drug/Fast Track/Special Designation
- 13.3.5 Geography
- 13.3.6 Type of Molecular Entity
- 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

## **14 K-STEMCELL CO LTD PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 14.1 K-Stemcell Co Ltd Business Profile
- 14.2 K-Stemcell Co Ltd Progressive Supranuclear Palsy (PSP) Drug Details
- 14.3 Drug Snapshot
  - 14.3.1 Originator
  - 14.3.2 Collaborator/Co-Developer
  - 14.3.3 Route of Administration
  - 14.3.4 Orphan Drug/Fast Track/Special Designation
  - 14.3.5 Geography
  - 14.3.6 Type of Molecular Entity
  - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

## **15 MERCK & CO INC PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 15.1 Merck & Co Inc Business Profile
- 15.2 Merck & Co Inc Progressive Supranuclear Palsy (PSP) Drug Details
- 15.3 Drug Snapshot
  - 15.3.1 Originator
  - 15.3.2 Collaborator/Co-Developer
  - 15.3.3 Route of Administration
  - 15.3.4 Orphan Drug/Fast Track/Special Designation
  - 15.3.5 Geography

- 15.3.6 Type of Molecular Entity
- 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

## **16 PRANA BIOTECHNOLOGY LTD PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 16.1 Prana Biotechnology Ltd Business Profile
- 16.2 Prana Biotechnology Ltd Progressive Supranuclear Palsy (PSP) Drug Details
- 16.3 Drug Snapshot
  - 16.3.1 Originator
  - 16.3.2 Collaborator/Co-Developer
  - 16.3.3 Route of Administration
  - 16.3.4 Orphan Drug/Fast Track/Special Designation
  - 16.3.5 Geography
  - 16.3.6 Type of Molecular Entity
  - 16.3.7 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

## **17 PROTHENA CORP PLC PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 17.1 Prothena Corp Plc Business Profile
- 17.2 Prothena Corp Plc Progressive Supranuclear Palsy (PSP) Drug Details
- 17.3 Drug Snapshot
  - 17.3.1 Originator
  - 17.3.2 Collaborator/Co-Developer
  - 17.3.3 Route of Administration
  - 17.3.4 Orphan Drug/Fast Track/Special Designation
  - 17.3.5 Geography
  - 17.3.6 Type of Molecular Entity
  - 17.3.7 Current Status
- 17.4 Drug Overview

- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

## **18 TAURX THERAPEUTICS LTD PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 18.1 TauRx Therapeutics Ltd Business Profile
- 18.2 TauRx Therapeutics Ltd Progressive Supranuclear Palsy (PSP) Drug Details
- 18.3 Drug Snapshot
  - 18.3.1 Originator
  - 18.3.2 Collaborator/Co-Developer
  - 18.3.3 Route of Administration
  - 18.3.4 Orphan Drug/Fast Track/Special Designation
  - 18.3.5 Geography
  - 18.3.6 Type of Molecular Entity
  - 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

## **19 UCB SA PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 19.1 UCB SA Business Profile
- 19.2 UCB SA Progressive Supranuclear Palsy (PSP) Drug Details
- 19.3 Drug Snapshot
  - 19.3.1 Originator
  - 19.3.2 Collaborator/Co-Developer
  - 19.3.3 Route of Administration
  - 19.3.4 Orphan Drug/Fast Track/Special Designation
  - 19.3.5 Geography
  - 19.3.6 Type of Molecular Entity
  - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

## **20 VOYAGER THERAPEUTICS INC PROGRESSIVE SUPRANUCLEAR PALSY (PSP) PIPELINE DETAILS**

- 20.1 Voyager Therapeutics Inc Business Profile
- 20.2 Voyager Therapeutics Inc Progressive Supranuclear Palsy (PSP) Drug Details
- 20.3 Drug Snapshot
  - 20.3.1 Originator
  - 20.3.2 Collaborator/Co-Developer
  - 20.3.3 Route of Administration
  - 20.3.4 Orphan Drug/Fast Track/Special Designation
  - 20.3.5 Geography
  - 20.3.6 Type of Molecular Entity
  - 20.3.7 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

## **21. LATEST PROGRESSIVE SUPRANUCLEAR PALSY (PSP) DRUG PIPELINE DEVELOPMENTS, 2019**

### **22. APPENDIX**

- 22.1 About Us
- 22.2 Sources and Methodology
- 22.3 Contact Information

## I would like to order

Product name: 2019 Future of Progressive Supranuclear Palsy (PSP) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2F07FC30DDDEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2F07FC30DDDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970